ASCO24 Updates: Dr. Akihito Kawazoe on Regorafenib and Nivolumab for Advanced Gastric Cancer

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Dr. Akihito Kawazoe from the National Cancer Center Hospital in Japan, shares insights on ‘First-line regorafenib with nivolumab and FOLFOX or CapeOX in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A single-arm, phase Ib/II trial‘

Hello everyone, I’m Akihito Kawazoe, GI oncologist in National Cancer Center Hospital in Japan. Today, I present the first-line regular regorafenib and nivolumab combined with chemotherapy including the K-pox regimen in patients with advanced gastric cancer in first-line setting. So, we previously reported promising results of regular regorafenib plus nivolumab for patients with gastric cancer in third or later line.

Recently, first-line regular regorafenib plus nivolumab combined with 4-FOX showed a promising result in United States trial. In clinical practice, K-pox requires less frequent clinical outpatient visit than 4-FOX in Asian country. Based on the above, we investigate the efficacy and safety of regular regorafenib plus nivolumab combined with chemotherapy including a K-pox regimen in first-line setting.

In this trial, two cohorts were set. Cohort A included K-pox regimen and cohort B included 4-FOX regimen. The primary endpoint is objective response rate in the phase 2 part.

So, as a result, the objective response was 73% and the DCR was 94%. Median PFS was 8.3 months. This combination had manageable safety profiling.

Translational research showed a reduction of activated regulatory T cell in patient with response. In conclusion, this combination showed a promising result in first-line setting in gastric cancer. Further investigation are required.

More videos and content from ASCO 2024 on OncoDaily.